Dyslipidemia

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹.

A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

Proprotein convertase subtilisin/kexin type 9 inhibitors for heterozygous familial hypercholesterolemia: A clinical practice experience from the SAFEHEART registry